| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1817 | 1509 | 14 |
| Full Text Views | 15 | 2 | 1 |
| PDF Downloads | 11 | 0 | 0 |
American Society of Tropical Medicine and Hygiene Symposium: Strategy for Plasmodium falciparum Vaccine Development and Clinical Trials: Panel Discussion
Jeffrey Chulay
Jeffrey Chulay
Search for other papers by Jeffrey Chulay in
Current site
Google Scholar
PubMed
Search for other papers by Jeffrey Chulay in
Current site
Google Scholar
PubMed
Raphael Mannino
Raphael Mannino
Search for other papers by Raphael Mannino in
Current site
Google Scholar
PubMed
Search for other papers by Raphael Mannino in
Current site
Google Scholar
PubMed
Peter Reeve
Peter Reeve
Search for other papers by Peter Reeve in
Current site
Google Scholar
PubMed
Search for other papers by Peter Reeve in
Current site
Google Scholar
PubMed
William Weidanz
William Weidanz
Search for other papers by William Weidanz in
Current site
Google Scholar
PubMed
Search for other papers by William Weidanz in
Current site
Google Scholar
PubMed
James Young
James Young
Search for other papers by James Young in
Current site
Google Scholar
PubMed
Search for other papers by James Young in
Current site
Google Scholar
PubMed
In addition to the panelists, several of the symposium speakers participated in the discussion. Other participants from the floor were Ross Coppel (Walter and Eliza Hall Institute, Melbourne, Australia), Robert Desowitz (University of Hawaii, Honolulu, Hawaii), Arnold Satterthwait (Research Instituteof Scripps Clinic, La Jolla, California), Allan Saul (Queensland Institute of Medical Research, Brisbane, Australia), Joseph Cohen (Smith Kline Beecham, Rixensart, Belgium), Margaret Pinder (IIRSDA Abidjan, Cote d'Ivoire).
Antigen Selection. Dr. Chulay: I would like to start by asking Dr. Peter Reeve to comment on the proposed antigen selection strategy that Dr. Russell Howard described.
Dr. Reeve: For several reasons, I regard the selection of antigens for development into experimental vaccines for human trials to be the most important step in vaccine development. First, it implies commitment of significant resources, including funds. In industry this decision is reviewed at the very highest levels. It also makes a very visible statement of intent: expectations are therefore likely to be high.
Author Notes
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1817 | 1509 | 14 |
| Full Text Views | 15 | 2 | 1 |
| PDF Downloads | 11 | 0 | 0 |